Hostname: page-component-7c8c6479df-nwzlb Total loading time: 0 Render date: 2024-03-28T05:19:51.573Z Has data issue: false hasContentIssue false

Correlates of In-Hospital COVID-19 Deaths: A Competing Risks Survival Time Analysis of Retrospective Mortality Data

Published online by Cambridge University Press:  25 March 2021

Ashish Goel*
Affiliation:
Department of Medicine, UCMS and GTB Hospital, Delhi
Alpana Raizada
Affiliation:
Department of Medicine, UCMS and GTB Hospital, Delhi
Ananya Agrawal
Affiliation:
Hamdard Institute of Medical Sciences and Research, New Delhi, India
Kamakshi Bansal
Affiliation:
UCMS and GTB Hospital, Delhi, India
Saurabh Uniyal
Affiliation:
UCMS and GTB Hospital, Delhi, India
Pratima Prasad
Affiliation:
Department of Pedodontics and Preventive Dentistry, UCMS and GTB Hospital, Delhi, India
Anil Yadav
Affiliation:
Department of Medicine, UCMS and GTB Hospital, Delhi
Asha Tyagi
Affiliation:
Department of Anesthesia, UCMS and GTB Hospital, Delhi, India
RS Rautela
Affiliation:
Department of Anesthesia, UCMS and GTB Hospital, Delhi, India
*
Corresponding author: Ashish Goel, Email: ashgoe@gmail.com.
Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Several aspects of the coronavirus disease 2019 (COVID-19) pandemic remain ambiguous, including its transmission, severity, geographic, and racial differences in mortality. These variations merit elaboration of local patterns to inform wider national policies.

Methods:

In a retrospective analysis, data of patients treated at a dedicated COVID hospital with moderate and severe illness during 8 wk of the pandemic were reviewed with attention to mortality in a competing risks framework.

Results:

A total of 1147 patients were hospitalized, and 312 (27.2%) died in hospital. Those who died were older (56.5 vs 47.6 y; P < 0.0001). Of these, 885 (77.2%) had tested positive on reverse transcriptase polymerase chain reaction (RT-PCR), with 219 (24.2%) deaths (incidence rate, 1.9 per 100 person-days). Median time from onset of symptoms to death was 11 days. A competing risks analysis for in-hospital death revealed an adjusted cause-specific hazard ratio of 1.4 for each decade increase in age.

Conclusions:

This retrospective analysis provides broad patterns of disease presentation and mortality. Even COVID test-negative patients will receive treatment at dedicated facilities, and 33% presenting cases may die within the first 72 h, most with comorbid illness. This should be considered while planning distribution of services for effective health-care delivery

Type
Original Research
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© Society for Disaster Medicine and Public Health, Inc. 2021

The severe acute respiratory syndrome coronavirus (SARS CoV-2) has impacted every aspect of human life globally in a few months after the World Health Organization (WHO) declared it a public health emergency of international concern. As the world prepares itself to receive the vaccines developed at an unprecedented speed and other novel therapies, several questions remain unanswered, even while newer ones emerge every day.

While people struggled with a psychological disaster in addition to a physical illness, the definition of what constituted a COVID death remained obscure, with considerable regional variations, for a long time. Reference Pulla1Reference Agarwal, Sharma and Gupta3 However, the variations in mortality rates and disease severity with geographic and racial diversity cannot be attributed to procedural differences alone. During the past year, there have been more than 90 million global cases of COVID-19, and nearly 2 million deaths. 4

While the case fatality rate (CFR) has been high in countries such as Yemen (29%), Mexico (8.7%), Hubei, China (6.6%), and United Kingdom (2.6%), it has been markedly lower in New Zealand (1.1%), Turkey (1%), and other neighboring countries of India such as Nepal (0.7%) and Sri Lanka (0.49%). 5 India has had 150,000 deaths in 10 million cases, which is far lower than in many countries, and a consistent CFR under 2%. 5 In addition to a remarkable variation in the CFR between countries, considerable differences for in-hospital mortality have been noted, ranging from 20% to 50% in different series. Reference Karagiannidis, Mostert and Hentschker6 While interpretation of the CFR itself is complex, it has been proposed that CFR computation and interpretation should include estimation of the time interval between the onset of illness and death. Reference Kobayashi, Jung and Linton7 A reliable estimate of CFR maybe possible only after right censoring for the duration. Additionally, limited testing and challenges in the attribution of the cause of death could be confounders in estimating the true CFR from the disease.

The variations in mortality have been attributed to racial differences, including immunity, demographic characteristics involving age composition of the affected population, hospitalization criteria, availability of intensive care, administrative decision-making including early and effective social lockdown, effectiveness of health care, testing strategies used, as well as the definition used to identify a COVID-death. The day-to-day variation in Wuhan had even been associated to changes in temperature and humidity. Reference Ma, Zhao and Liu8 Not only does the quality of reporting influence the recording of deaths, but the phase of the pandemic could also determine its intensity. While the impact of early implementation of public health measures cannot be over-emphasized, it is noteworthy that the role of diet, meal timing, glutathione deficiency, ethnicity, genetic susceptibility, blood group, chest diameter, and air pollution have all been invoked in the literature. Reference Bousquet, Anto and Czarlewski9Reference Verd, Beiro and Fernandez-Bernabeu19 Yet, none of these are entirely convincing, and the comprehensive picture continues to elude us. Reports from China, Italy, and the United States have suggested that risk factors for severe disease include older age and presence of comorbid conditions such as diabetes and hypertension. 20Reference Huang, Wang and Li24

The assumption that older patients in India would have a similar risk of severe disease and unfavorable outcome has guided the Indian public health response. However, initial Indian data suggested that younger people died at a higher rate than was expected (37%) from the Italian studies. 25,Reference Philip, Ray and Subramanian26 Health-related data during COVID times are sparse, despite marked regional differences in public health statistics related to cases, recovery, and death. The reported positivity rate in cities such as Delhi, Mumbai, and Ahmedabad has been nearly 5-times higher than the national average. 25 This diversity underscores the need to closely analyze local data to determine unique characteristics that could guide national policy and local action.

The present study aimed to analyze the demographic and clinical profile of patients with COVID-19 who succumbed to illness in our hospital while accounting for the effect of gender, clinical presentation, and comorbid conditions on mortality.

Methods

A retrospective analysis of patient data for individuals hospitalized during 8 wk of the pandemic between June 20 and August 15, 2020, was conducted at our large tertiary-care public facility in Delhi, operating as a COVID-19–dedicated hospital during this period. Data collected for national/state level monitoring were analyzed after an approval by the Institutional Ethics Committee for human research.

The exposure variables for analysis included clinical features such as cough, breathlessness, fever, myalgia, conjunctivitis, headache, etc. Presence of pre-existing comorbid conditions such as diabetes, hypertension, chronic obstructive airway disease (COAD), chronic kidney disease (CKD), cardiovascular disease (CVD), etc. was recorded. The dates of onset of symptoms, hospitalization, deterioration in health condition, discharge, and death were noted.

The data were examined using Stata (version 13, Stata Inc, USA) and were interrogated to determine association of age, sex, clinical presentation, and presence of comorbidity with outcome. Age was analyzed as a continuous variable and was also recoded into categories defined by decades where relevant. Groups were determined by outcome (discharge or death) and by COVID-19 test report (positive or negative). Differences across groups were examined using chi-squared test or t-test as applicable. A survival time analysis using the duration of illness from symptom onset until outcome was carried out and Kaplan-Meier survival estimates were computed. A competing risks survival time analysis was conducted for in-hospital death and discharge, and sub-distribution hazard ratios are reported.

Results

A total of 1147 adult patients with a mean age of 50.0 y (±16.5 y) were hospitalized to our facility between June and August with symptoms suggestive of COVID-19 illness. Of these, 635 (55.4%) were males. A flow diagram of the study and the results is presented in Figure 1.

Figure 1. Flow diagram of the study.

As many as 885 (77.2%) patients were confirmed positive on reverse transcriptase polymerase chain reaction (RT-PCR) and were not significantly older (50.2 ± 15.9 y) than the 232 who tested negative (48.4 ± 18 y; P = 0.15). Results of 30 (2.6%) tests were not available.

A total of 312 (27.2%) deaths were reported during the observation period in our hospital. Proportion of death among 885 who tested COVID-19 positive (n = 219; 24.8%) was lower than among the 232 who tested negative (n = 82; 35.3%; P = 0.001). Among those who tested positive, males had a higher probability of death (n = 138; 28.7%) compared to females (n = 81; 20.1%, P = 0.004). Among the COVID-19 positive patients, it was noted that more than a third of the patients (n = 81; 37%) died within the first 72 h of hospitalization.

After adjusting for sex and COVID-19 test status, advancing age was found to be significantly associated with death. Each decade increase in age was associated with an increase in odds of 1.4 times (P < 0.001; 95% confidence interval [CI], 1.3-1.6). The age distribution of COVID-19 patients is presented in Figure 2.

Figure 2. Age distribution of COVID-19 patients.

Among the COVID-19 patients who tested positive, the 219 patients who died were significantly older (58.8 ± 13.7 y) than the other 666 who recovered (47.3 ± 15.6 y; P < 0.001). The mean age at the time of death did not differ by sex. A distribution of hospital admissions across the observation period is presented in Figure 3.

Figure 3. Distribution of hospital admissions.

Data on clinical presentation were available for 116 patients who had died. Most (n = 101; 87.1%) had presented to the hospital with breathlessness, while fewer had fever (n = 63; 54.3%) and cough (n = 49; 42.2%). Of these, 61 patients (53.5%) fulfilled the definition of severe acute respiratory illness (SARI) at the time of hospitalization. The pre-existing comorbid conditions included diabetes (n = 54; 46.6%), hypertension (n = 47; 40.5%), CKD (n = 21; 18.1%), and CVD (n = 23; 19.8%). Seven (6%) patients had a past history of tuberculosis, and 2 (1.7%) had COAD. Ninety-one (78.4%) patients had at least 1 or more comorbid illness. A distribution of comorbid conditions among the COVID-19 patients who died is presented in Figure 4.

Figure 4. Comorbidity in COVID-19 patients who died.

Patients contributed 11,287 observation days for a survival-time analysis for the duration of hospital stay. The median hospital stay for all patients included in the analysis, was 8 days (interquartile range [IQR], 3-14 d). Those who died in the hospital had a mean stay of 6 d (95% CI, 5.1-6.7), while those who recovered remained hospitalized for 12 d (95% CI, 11.4-12.5; P < 0.001). The incidence rate of in-hospital death among the COVID-19 positive patients in hospital was 1.9 per 100 person-days. The Kaplan-Meier survival curves by sex are presented in Figure 5 and by age category (old ≥ 60 y; young < 60 y) in Figure 6.

Figure 5. Kaplan-Meier survival function for hospital stay by sex.

Figure 6. Kaplan-Meier survival function for hospital stay by age category.

A competing risks analysis for in-hospital death reveals a cause-specific hazard ratio of 1.4 (95% CI, 1.3-1.5) for each decade increase in age after adjusting for sex and COVID-19 test result. The cumulative incidence function distribution by age category (old vs young) for in-hospital death is presented in Figure 7. A competing risk analysis for discharge reveals a cause-specific hazard ratio of 0.8 (95%CI, 0.76-0.84) for each decade increase in age after adjusting for sex and COVID-19 test result. The cumulative incidence function distribution by age (old vs young) for discharge is presented in Figure 8.

Figure 7. Competing risks analysis for in-hospital mortality.

Figure 8. Competing risks regression analysis for discharge.

A total of 81 COVID-19 positive patients, who succumbed to illness, contributed 1016 observation days for survival analysis from onset of symptoms. Median time to death was 11 d (IQR, 7-16) from the onset of symptoms. The Kaplan Meier survival function for death from onset of symptoms is presented in Figure 9.

Figure 9. Kaplan-Meier survival function for death resented by sex.

Discussion

Understanding the factors associated with death has been an area of interest in recent pandemic times. Kobayashi et al. have argued that, in a disease such as COVID-19, a simple CFR may not be enough to understand the disease due to its peculiar nature that merits estimation of time to death in view of several cases continuing to be sick at any given time. Reference Kobayashi, Jung and Linton7

By this time, there are previous data from developed countries describing associations of mortality in COVID-19. A large body of data regarding the profile of patients appears from Wuhan, Reference Ma, Zhao and Liu8,Reference Huang, Wang and Li24,Reference Du, Tu and Zhu27Reference Zhou and Tan35 followed by a few European countries Reference Karagiannidis, Mostert and Hentschker6,Reference Colaneri, Sacchi and Zuccaro21,Reference Escalera-Antezana, Lizon-Ferrufino and Maldonado-Alanoca22,Reference Bonetti, Manelli and Patroni36Reference Berenguer, Ryan and Rodríguez-Baño40 and scantily from other developing countries. Reference Tambe, Parande and Tapare41Reference Hernández-Vásquez, Azañedo and Vargas-Fernández44

We have observed a CFR of 24.8%, which is lower than 29.4% reported in the only available mortality related analysis from India by Tambe et al. Reference Tambe, Parande and Tapare41 However, our results reflect the distribution from a 5-times larger cohort than the earlier study (1147 vs 197). The mortality noted by us is close to that reported by Karagiannidis et al. in a large cohort analysis across German hospitals including 10,021 hospitalized patients. Reference Karagiannidis, Mostert and Hentschker6 A much lower mortality of 16.1% among 701 patients was reported by Cheng et al. from their hospital in Wuhan. Reference Cheng, Luo and Wang45

The adverse effect of advancing age on mortality has been identified in many countries. Reference Li, Wang and Yan29,Reference Zangrillo, Beretta and Scandroglio39,Reference Berenguer, Ryan and Rodríguez-Baño40,Reference Iaccarino, Grassi and Borghi46Reference Zhang, Zhou and Qiu48 The presence of pre-existing comorbidity has been established as a risk for severe disease and mortality. Reference Li, Wang and Yan29,Reference De Vito, Geremia and Fiore37,Reference Zangrillo, Beretta and Scandroglio39,Reference Berenguer, Ryan and Rodríguez-Baño40,Reference Hernández-Galdamez, González-Block and Romo-Dueñas43,Reference Hernández-Vásquez, Azañedo and Vargas-Fernández44,Reference Iaccarino, Grassi and Borghi46Reference Mantovani, Byrne and Zheng50 Our findings are in sync with the international literature with hypertension and diabetes emerging as the commonest comorbid illnesses. In a slight deviation from these consistent results, the Italian model to predict death noted that while co-existing diabetes, CKD, and COPD exaggerated the risk of death, hypertension did not. Reference Iaccarino, Grassi and Borghi46 This may be explained by the variation in severity and control of hypertension. Also, Rottoli et al. identified obesity as another risk factor in a retrospective analysis of 482 Italian patients. Reference Rottoli, Bernante and Belvedere51 Obesity could be a markedly different health variable in developing versus developed countries. Using a novel health analytics platform, Williamson et al. have reported that deprivation and presence of comorbid illness conferred greater risk of mortality. Reference Williamson, Walker and Bhaskaran47

Although our study does not include laboratory parameters for their evaluation as prognostic markers there are previous data for the same. Reference Li, Wang and Yan29,Reference Bonetti, Manelli and Patroni36,Reference De Vito, Geremia and Fiore37,Reference Berenguer, Ryan and Rodríguez-Baño40,Reference Chen, Yu and He52Reference Yang, Yang and Zhang59 Increase in indicators such as neutrophils, neutrophil-leukocyte ratio, lactate dehydrogenase, troponin, d-dimer, C-reactive protein, creatinine, urea, interleukins, and markers of cardiac injury have been associated with a poorer prognosis.

We have noted an adjusted hazard ratio of 1.4 for mortality with every decade increase in age. The association of increasing age and gender variation in COVID-related mortality has been noticed by Zhang et al. in a retrospective review of 82 deaths in Wuhan, with 65.9% of the victims being men and 80.5% older than 60 y. Reference Zhang, Zhou and Qiu48 In similar experiences from Milan and Spain, older persons had a greater chance of dying. Reference Zangrillo, Beretta and Scandroglio39,Reference Berenguer, Ryan and Rodríguez-Baño40

We note that hospital stay was longer for survivors compared to non-survivors, irrespective of positivity on RT-PCR test for COVID-19. Karagiannidis et al. have also reported that a hospital stay of more than 18 days was associated with increased chances of survival. Reference Karagiannidis, Mostert and Hentschker6 This could be an encouraging finding when clinically attending to patients with prolonged hospital stay.

In an earlier analysis from our center, we have reported that 7.6% patients presenting with mild symptoms in the early pandemic phase in our city were found positive for COVID-19. Reference Goel, Raizada and Bansal42 The positivity rate among the moderate-severely ill patients who needed hospitalization in the present phase of the pandemic appears much higher at 77%. Also, the patients presenting during the early phase for testing were a decade younger (41 y) than those who needed hospitalization currently (50 y). This serves to highlight the changing nature of health services required as the pandemic continues to evolve, and is vital to planning services in any country.

The present study is the first study in which mortality from COVID-19 illness has been evaluated in a competing risk analysis framework and is also the largest series of patients who succumbed to the COVID-19 illness from India. Our study establishes that COVID-19–positive patients did not have a higher probability of death than those who were negative but presented with similar symptoms. In addition, we report that patients who are COVID-19 positive have a longer hospital stay after adjusting for age, sex, and outcome. We recognize the limitations in our study posed by gaps in our health-related data or indeterminate test reports and suggest that electronic medical records and hospital information systems could make data collection in developing countries more robust. It is interesting to note that, despite remarkable differences in the CFR in our country, the age and comorbidity profile of our patients is strikingly similar to the Western literature. Studies focusing on other key parameters, including host immunity, virus characteristics, and service delivery, would be able to ascertain the causes of lower mortality rates being reported from our region.

Conclusions

This retrospective analysis allows us to provide answers to some broad patterns of disease presentation and its progression among different groups of individuals (differentiated by age and sex). Nearly 1 in 4 patients even at a dedicated facility may be COVID-19 negative and often too sick to shift to alternate facilities. Clinicians and administrators need to make arrangements to segregate and manage these individuals. Nearly 1 in 3 patients who succumb to illness in the hospital are likely do so within the first 72 h. In addition, those who die are likely to be older, with each advancing decade, conferring additional significant mortality risk. This should be considered while planning distribution of services. Nearly 4 of 5 patients who succumb to illness have associated comorbidity. Our findings reiterate the need for early diagnosis, testing, and multidisciplinary management. Within clinical facilities these inferences shall allow informed decision making for seamless, effective, and sustained health-care services to reduce mortality.

Acknowledgments

The authors acknowledge the guidance provided by Dr. Karen Bandeen Roche, Hurley Dorrier Professor and Chair in Biostatistics at the Johns Hopkins Bloomberg School of Public Health, USA. Dr. Bandeen-Roche introduced us to a competing risks analysis framework and also guided us toward the appropriate approach.

Author Contributions

A.G.: Involved in designing the study, developing the research questions, analyzing the data, writing the manuscript, reviewed the final manuscript, approved the final submission. A.R.: Involved in designing the study, developed the research questions, wrote the manuscript, reviewed the final manuscript and approved the final submission. A.A.: Involved in data compilation, data cleaning, reviewed the final manuscript and approved the final submission. K.B.: Involved in data compilation, data cleaning, analyzing the data, reviewed the final manuscript and approved the final submission. S.U.: Involved in data compilation, reviewed the final manuscript and approved the final submission. A.K.Y.: Involved in designing the study, developing the research questions, reviewed the final manuscript, approved the final submission. P.P.: Involved in designing the study, data collection and cleaning, reviewed the final manuscript, approved the final submission. A.T. and R.S.A.: Involved in designing the study, developing the research questions, reviewed the final manuscript, approved the final submission.

References

Pulla, P. What counts as a covid-19 death? BMJ. 2020;370:m2859.CrossRefGoogle ScholarPubMed
Slater, TA, Straw, S, Drozd, M, et al. Dying ‘due to’ or ‘with’ COVID-19: a cause of death analysis in hospitalised patients. Clin Med (Lond). 2020;20(5):e189e190.CrossRefGoogle ScholarPubMed
Agarwal, V, Sharma, S, Gupta, L, et al. COVID-19 and psychological disaster preparedness - an unmet need. Disaster Med Public Health Prep. 2020;14(3):387390.CrossRefGoogle ScholarPubMed
World Health Organization. Coronavirus disease (COVID-19) pandemic 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed April 13, 2021.Google Scholar
Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins. 2020. https://coronavirus.jhu.edu/map.html. Accessed April 13, 2021.Google Scholar
Karagiannidis, C, Mostert, C, Hentschker, C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):3031630317.CrossRefGoogle ScholarPubMed
Kobayashi, T, Jung, SM, Linton, NM, et al. Communicating the risk of death from novel coronavirus disease (COVID-19). J Clin Med. 2020;9(2):580.CrossRefGoogle Scholar
Ma, Y, Zhao, Y, Liu, J, et al. Effects of temperature variation and humidity on the death of COVID-19 in Wuhan, China. Sci Total Environ. 2020;724:138226.CrossRefGoogle ScholarPubMed
Bousquet, J, Anto, JM, Czarlewski, W, et al. Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. Allergy. 2021;76(3):735750.CrossRefGoogle ScholarPubMed
Aldridge, RW, Lewer, D, Katikireddi, SV, et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res. 2020;5:88.Google ScholarPubMed
Bousquet, J, Anto, JM, Iaccarino, G, et al. Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020;10:16.CrossRefGoogle ScholarPubMed
Ferrante, G, Fazzari, F, Cozzi, O, et al. Risk factors for myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography. Cardiovasc Res. 2020;116(14):22392246.CrossRefGoogle ScholarPubMed
Fountoulakis, KN, Fountoulakis, NK, Koupidis, SA, et al. Factors determining different death rates because of the COVID-19 outbreak among countries. J Public Health (Oxf). 2020;42(4):681687.CrossRefGoogle ScholarPubMed
Giudicessi, JR, Roden, DM, Wilde, AAM, et al. Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. Heart Rhythm. 2020;17(9):14871492.CrossRefGoogle ScholarPubMed
Hultström, M, Persson, B, Eriksson, O, et al. Blood type A associates with critical COVID-19 and death in a Swedish cohort. Crit Care. 2020;24(1):496.CrossRefGoogle Scholar
Leaf, RK, Al-Samkari, H, Brenner, SK, et al. ABO phenotype and death in critically ill patients with COVID-19. Br J Haematol. 2020;190(4):e204e208.Google ScholarPubMed
Mehmood, K, Saifullah, Abrar MM, et al. Can PM(2.5) pollution worsen the death rate due to COVID-19 in India and Pakistan? Sci Total Environ. 2020;742:140557.CrossRefGoogle Scholar
Polonikov, A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis. 2020;6(7):15581562.CrossRefGoogle ScholarPubMed
Verd, S, Beiro, S, Fernandez-Bernabeu, M, et al. Early dinner or “dinner like a pauper”: evidence, the habitual time of the largest meal of the day - dinner - is predisposing to severe COVID-19 outcome - death. Chronobiol Int. 2020;37(6):804808.CrossRefGoogle ScholarPubMed
CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morbid Mortal Wkly Rep. 2020;69(13):382386.CrossRefGoogle Scholar
Colaneri, M, Sacchi, P, Zuccaro, V, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill. 2020;25(16):2000460.CrossRefGoogle ScholarPubMed
Escalera-Antezana, JP, Lizon-Ferrufino, NF, Maldonado-Alanoca, A, et al. Clinical features of the cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. Travel Med Infect Dis. 2020;35:101653.CrossRefGoogle Scholar
Guan, WJ, Liang, WH, Zhao, Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.CrossRefGoogle ScholarPubMed
Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497506.CrossRefGoogle ScholarPubMed
Indian Ministry of Health and Family Welfare. COVID-19 India: Government of India. 2020. https://www.mohfw.gov.in/. Accessed April 13, 2021.Google Scholar
Philip, M, Ray, D, Subramanian, S. Decoding India’s low Covid-19 case fatality rate: National Bureau of Economics Research; 2020. https://ssrn.com/abstract=3675248. Accessed April 13, 2021.Google Scholar
Du, Y, Tu, L, Zhu, P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):13721379.CrossRefGoogle ScholarPubMed
Li, Q, Guan, X, Wu, P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):11991207.CrossRefGoogle ScholarPubMed
Li, X, Wang, L, Yan, S, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128132.CrossRefGoogle Scholar
Qin, C, Zhou, L, Hu, Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 202071(15):762768.Google Scholar
Wu, C, Chen, X, Cai, Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;180(7):934943.CrossRefGoogle ScholarPubMed
Yang, J, Zheng, Y, Gou, X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:9195.CrossRefGoogle Scholar
Zhang, JJ, Dong, X, Cao, YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):17301741.CrossRefGoogle ScholarPubMed
Zhou, F, Yu, T, Du, R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):10541062.CrossRefGoogle ScholarPubMed
Zhou, J, Tan, J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020;107:154216.CrossRefGoogle ScholarPubMed
Bonetti, G, Manelli, F, Patroni, A, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. Clin Chem Lab Med. 2020;58(7):11001105.CrossRefGoogle ScholarPubMed
De Vito, A, Geremia, N, Fiore, V, et al. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy. Eur Rev Med Pharmacol Sci. 2020;24(14):78617868.Google ScholarPubMed
Grasselli, G, Zangrillo, A, Zanella, A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):15741581.CrossRefGoogle ScholarPubMed
Zangrillo, A, Beretta, L, Scandroglio, AM, et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc. 2020. Online ahead of print.Google Scholar
Berenguer, J, Ryan, P, Rodríguez-Baño, J, et al. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26(11):15251536.CrossRefGoogle Scholar
Tambe, MP, Parande, MA, Tapare, VS, et al. An epidemiological study of laboratory confirmed COVID-19 cases admitted in a tertiary care hospital in Pune, Maharashtra. Indian J Public Health. 2020;64(Suppl):S183S187.CrossRefGoogle Scholar
Goel, A, Raizada, A, Bansal, K, et al. Profile of patients suspected to be COVID-19: a retrospective analysis of early pandemic data. Cureus. 2020;12(8):e10125.Google ScholarPubMed
Hernández-Galdamez, DR, González-Block, M, Romo-Dueñas, DK, et al. Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Arch Med Res. 2020;51(7):683689.Google ScholarPubMed
Hernández-Vásquez, A, Azañedo, D, Vargas-Fernández, R, et al. Association of comorbidities with pneumonia and death among COVID-19 patients in Mexico: a nationwide cross-sectional study. J Prev Med Public Health. 2020;53(4):211219.CrossRefGoogle ScholarPubMed
Cheng, Y, Luo, R, Wang, K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829838.CrossRefGoogle ScholarPubMed
Iaccarino, G, Grassi, G, Borghi, C, et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension. Hypertension. 2020;76(2):366372.CrossRefGoogle ScholarPubMed
Williamson, EJ, Walker, AJ, Bhaskaran, K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430436.CrossRefGoogle ScholarPubMed
Zhang, B, Zhou, X, Qiu, Y, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020;15(7):e0235458.CrossRefGoogle ScholarPubMed
García-Azorín, D, Martínez-Pías, E, Trigo, J, et al. Neurological comorbidity is a predictor of death in Covid-19 disease: a cohort study on 576 patients. Front Neurol. 2020;11:781.Google ScholarPubMed
Mantovani, A, Byrne, CD, Zheng, MH, et al. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30(8):12361248.CrossRefGoogle ScholarPubMed
Rottoli, M, Bernante, P, Belvedere, A, et al. How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre. Eur J Endocrinol. 2020;183(4):389397.CrossRefGoogle ScholarPubMed
Chen, L, Yu, J, He, W, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia. 2020;34(8):21732183.CrossRefGoogle ScholarPubMed
Chen, X, Yan, L, Fei, Y, et al. Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19. J Clin Lab Anal. 2020;34(10):e23467.CrossRefGoogle ScholarPubMed
Guo, L, Shi, Z, Zhang, Y, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis. Diabetes Res Clin Pract. 2020;166:108346.CrossRefGoogle ScholarPubMed
Li, J, Guo, T, Dong, D, et al. Defining heart disease risk for death in COVID-19 infection. QJM. 2020;113(12):876882.CrossRefGoogle ScholarPubMed
Li, X, Pan, X, Li, Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020;24(1):468.CrossRefGoogle ScholarPubMed
Pan, F, Yang, L, Li, Y, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020;17(9):12811292.CrossRefGoogle ScholarPubMed
Qin, W, Hu, BZ, Zhang, Z, et al. [Clinical characteristics and death risk factors of severe COVID-19]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(8):648653.Google ScholarPubMed
Yang, H, Yang, LC, Zhang, RT, et al. [Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes]. Beijing Da Xue Xue Bao Yi Xue Ban. 2020;52(3):420424.Google Scholar
Figure 0

Figure 1. Flow diagram of the study.

Figure 1

Figure 2. Age distribution of COVID-19 patients.

Figure 2

Figure 3. Distribution of hospital admissions.

Figure 3

Figure 4. Comorbidity in COVID-19 patients who died.

Figure 4

Figure 5. Kaplan-Meier survival function for hospital stay by sex.

Figure 5

Figure 6. Kaplan-Meier survival function for hospital stay by age category.

Figure 6

Figure 7. Competing risks analysis for in-hospital mortality.

Figure 7

Figure 8. Competing risks regression analysis for discharge.

Figure 8

Figure 9. Kaplan-Meier survival function for death resented by sex.